TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Plasma Cortisol Concentrations From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Blood Glucose Levels From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in White Blood Cell (WBC) Levels From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Breakthrough incidence of Invasive Fungal Infection (IFI)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-op CK-MB Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total intraoperative remifentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decrease in the number of RUTI exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Peripheral Platelet Count Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: β3 receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxidative stress assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to prescribed dieting
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Adherence in M/XDR-TB HIV outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of nail plate damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in patient relationship functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in partner relationship functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: MRD negative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-Tat Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prostate Cancer Progression-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: abstinence or drinking below recommended limits without problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral activation patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Persistence of colonization of L. reuteri
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pancreatic fistula grade B/C
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of ICD/CRT-D subjects with a ≥ 5 second delay in post-MRI VF detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of LV pacing leads with a LV pacing threshold increase > 1V between pre-MRI and one-month post-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Response to Brief Psychiatry Rating Scale (BPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate of Microdevice Retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with Microdevice Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of color change after dehydration period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shear Rheology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Characterisation of myositis subgroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N170 latency to upright faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in psychopathology (depression and anxiety symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Margin Reflex Distance 2 (MRD2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary iodine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD44 expression in cerebrospinal fluid (CSF), blood and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Outdoor Falls Questionnaire (OFQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Falls Behavioral Scale for the Older Person (FaB)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Falls Self-efficacy Scale- International (FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tooth post-bleaching sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Recovery T4/T1 Ratio to 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Content of natural IgM in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: success at 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with antibody titers of 1:40 or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local tolerability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentration observed (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration versus time curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Large LDL (LDL I + 2a) (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Large HDL (HDL2b) (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: LDL peak particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Change in Brief Autism Mealtime Behavior Inventory (BAMBIC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Sensory Experiences Questionnaire (SEQ 3.0)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Behavioral Pediatric Feeding Assessment Scale (BPFAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Goal Attainment Scaling (GAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Descemet membrane detachment resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with home blood glucose reporting
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ICU Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in pro- and anti-inflammatory protein levels after modified ultrafiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in pro- and anti-inflammatory protein levels at ICU admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacotherapy adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time until resolution of very high blood pressure episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin Wrinkle Depth and Redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin carotenoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence / absence of intra parietal calcification of lower limb arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Concordance of surgeon anatomy definition with fluorescence outline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for emergent CABG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fugl-Meyer Upper Extremity Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH-CPSI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IPSS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nutrition Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cancer-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: AUC(0-inf) of GP2013, MabThera and Rituxan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall sickness absence rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in health-related quality of life (HRQoL) by EQ-5D-5L utility value
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients without transfusion-dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occult cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Fatigue Severity Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: proportion of patients initiated on therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VO2 through gas exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood Lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: New-onset heart blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of dyspnea level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: glomerular filtration rate measured by inulin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hormone levels change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Amount of opioids used in PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily insulin requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence rate of acute and late toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Emotional Self Awareness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: User Performance evaluation - blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: System Accuracy evaluation - blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Joint and muscle pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Glucose Total Area Over the Curve and Less Than 60 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient's tolerance with the treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of cycles
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients experiencing dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Box and Block Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in fasting blood circulating serum TGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systemic pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milk Volume collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of cardiac amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: behavioral responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physiological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Area Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants to Discontinue Steroid Treatment After Rituximab
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants to Discontinue Steroid Treatment After Tocilizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of composite complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Distance Walked During the Six-minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cardiovascular (CV)-Related Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: All-cause Mortality (ACM)
Endpoint domain: Mortality/survival
Primary endpoint: Eckhard symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of acne severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant-rated Edmonton Symptom Assessment Scale (ESAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Selective Reminding Test (SRT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HbA1c mean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Short term clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Severity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sick leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accuracy of CT in diagnosing appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in mean glycated hemoglobin levels (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HIV-incidence rates
Endpoint domain: Mortality/survival
Primary endpoint: Isolation Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Openness of family communication related to adoption
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Subjects With In-office Tube Placement Procedure Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Tubes Successfully Placed Using a TTDS Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in renal blood flow (RBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of infusional toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of neutrophil recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median Pain Score During Shift 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline on MSPSQ-CSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Treatment Responders at Week 10 Using Clinical Global Impression (CGI-I) Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Daily consumption of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruises
Endpoint domain: Adverse events/effects
Primary endpoint: Pain (VAS-scale)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Are Stone Free at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Fat Percentage Estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower limb haemodynamic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with SpO2 below 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rScO2 desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary albumin creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Small Bowel Obstruction resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in BDI-II Depressive Symptom Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinically meaningful change in FSFI score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased of Vasomotor Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of reduction in wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma Lipid Profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: prosthesis survival rate
Endpoint domain: Mortality/survival
Primary endpoint: bone resorption, as evaluated with cone-beam computed tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-point MACE
Endpoint domain: Mortality/survival
Primary endpoint: 4D CMR Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to antiretroviral therapy (ART)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: anesthetic gas consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Physical Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measure of exhaled nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Variation of respiratory discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life 1 year after the second intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Biomarkers of Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Thalamocortical Functional Connectivity (FC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of changed forced expiratory volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Temperature Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Sum of the Score From the Activities of Daily Living (ADL) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Motor Examination in the Unified Parkinson's Disease Rating Scale (UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatment-emergent serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of TEAEs leading to treatment discontinuations
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Senile Purpura Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total Square Size of Purpuric Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Postprandial Serum Triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Postprandial Serum Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Postprandial Serum Inflammatory Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Fasting Serum Lipids and Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fasting Inflammatory Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Overall Lifting and Tightening of Treated Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pain and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects